STADA Arzneimittel AG (SAZ) Given a €66.25 Price Target by Warburg Research Analysts
STADA Arzneimittel AG (ETR:SAZ) has been given a €66.25 ($78.87) target price by equities researchers at Warburg Research in a research report issued to clients and investors on Wednesday. The brokerage currently has a “sell” rating on the stock.
A number of other brokerages have also issued reports on SAZ. S&P Global set a €63.00 ($75.00) price target on STADA Arzneimittel AG and gave the stock a “neutral” rating in a research note on Wednesday, June 28th. Commerzbank Ag set a €66.00 ($78.57) price target on STADA Arzneimittel AG and gave the stock a “neutral” rating in a research note on Saturday, May 20th. Kepler Capital Markets set a €58.00 ($69.05) price target on STADA Arzneimittel AG and gave the stock a “sell” rating in a research note on Wednesday, June 28th. Finally, Independent Research GmbH set a €76.00 ($90.48) price target on STADA Arzneimittel AG and gave the stock a “sell” rating in a research note on Tuesday. Four research analysts have rated the stock with a sell rating and two have assigned a hold rating to the company’s stock. STADA Arzneimittel AG presently has a consensus rating of “Sell” and an average target price of €67.71 ($80.61).
STADA Arzneimittel AG (ETR SAZ) opened at 77.601 on Wednesday. The firm has a 50-day moving average of €67.15 and a 200-day moving average of €62.43. STADA Arzneimittel AG has a 52-week low of €41.40 and a 52-week high of €84.20. The firm has a market cap of €4.83 billion and a PE ratio of 51.289.
COPYRIGHT VIOLATION WARNING: “STADA Arzneimittel AG (SAZ) Given a €66.25 Price Target by Warburg Research Analysts” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/09/01/stada-arzneimittel-ag-saz-given-a-66-25-price-target-by-warburg-research-analysts.html.
About STADA Arzneimittel AG
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.
Receive News & Stock Ratings for STADA Arzneimittel AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel AG and related stocks with our FREE daily email newsletter.